WO2005033323A1 - Process for producing 1,4-dihydoxy-2-naphthoic acid - Google Patents
Process for producing 1,4-dihydoxy-2-naphthoic acid Download PDFInfo
- Publication number
- WO2005033323A1 WO2005033323A1 PCT/JP2004/014394 JP2004014394W WO2005033323A1 WO 2005033323 A1 WO2005033323 A1 WO 2005033323A1 JP 2004014394 W JP2004014394 W JP 2004014394W WO 2005033323 A1 WO2005033323 A1 WO 2005033323A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- culture
- medium
- carbon source
- producing
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
- A23C9/1209—Proteolytic or milk coagulating enzymes, e.g. trypsine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- the present invention relates to a method for producing 1,4-dihydroxy-2-naphthoic acid (hereinafter also referred to as DHNA) at a high concentration using fermentation of propionic acid bacteria, and a technique for improving the flavor of a culture thereof.
- DHNA 1,4-dihydroxy-2-naphthoic acid
- DHNA has conventionally been known to be useful as an industrial material as a dye, a pigment, and a photosensitive material, and various synthetic methods have been developed by organic chemical synthesis methods.
- the present inventors studied alternative DHNA production methods and found that DHNA was produced in large quantities in and out of the cells by propionic acid bacteria, and the DHNA-containing composition collected from this culture, or 1 , 4-Dihydroxy-2-naphthoic acid or its salt has the effect of reducing the abdominal discomfort seen when ingesting milk with lactose intolerance, and that it is useful for the prevention and treatment of metabolic bone disease (Patent Document 1).
- Patent Document 1 4-Dihydroxy-2-naphthoic acid or its salt
- Patent Document 1 International Publication No. WO03Z016544 pamphlet
- the present inventors have conducted intensive studies from various angles to obtain a DHNA-containing composition with reduced bitterness.
- the culture medium was air-ventilated at a certain time during fermentation of propionic acid bacteria. This led to a useful new finding that the concentration of DHNA in the culture was increased. It was also found that the DHNA concentration was increased by adding a carbon source of propionic acid bacteria to the culture after culturing and storing at low temperature under weak alkaline conditions, even though the culturing was completed. .
- the DHNA-containing composition obtained by brute force suppresses bitterness, It was found that the taste was good and that it was useful as a food or drink or pharmaceutical.
- An object of the present invention is to provide a method for producing 1,4-dihydroxy-2 naphthoic acid, which comprises culturing by aeration in a medium.
- the present invention provides a method for culturing a 1,4-dihydroxy-2 naphthoic acid-producing bacterium belonging to a propionic acid bacterium under anaerobic conditions, adding a carbon source to the obtained culture, and culturing the solution at a temperature of 3 to 20 ° under a weak alkali.
- the present invention provides a method for producing 1,4-dihydroxy-2 naphthoic acid, which is stored in C.
- the present invention provides a method for culturing a 1,4-dihydroxy-2 naphthoic acid-producing bacterium belonging to a propionic acid bacterium under an anaerobic condition, and when the carbon source concentration in the medium becomes 3.5% by mass or less,
- a method for producing 1,4-dihydroxy-2 naphthoic acid characterized in that the culture is obtained by aeration, and a carbon source is added to the resulting culture and stored at 3-20 ° C under weak alkaline conditions. Is what you do.
- the present invention also provides a 1,4-dihydroxy-2 naphthoic acid-containing composition obtained as described above.
- the present invention provides a food and beverage for improving abdominal discomfort symptoms, an agent for improving abdominal discomfort symptoms, an agent for preventing and treating metabolic bone diseases, which comprises the 1,4-dihydroxy-2 naphthoic acid-containing composition obtained as described above as an active ingredient. It is intended to provide a food or drink or an agent for preventing or treating metabolic bone disease.
- the present invention also relates to a food and drink for improving abdominal discomfort symptoms, an agent for improving abdominal discomfort symptoms, a food and drink for preventing and treating metabolic bone disease, or a metabolic food or drink, of the 1,4-dihydroxy-2 naphthoic acid-containing composition obtained as described above.
- the present invention also provides use of the composition for the prevention and treatment of bone diseases.
- the present invention also provides administration of an effective amount of the 1,4-dihydroxy-2 naphthoic acid-containing composition obtained as described above. It is intended to provide a method for treating abdominal discomfort or a method for treating metabolic bone disease.
- DHNA can be produced efficiently, and the obtained DHNA-containing composition has a good flavor and is useful as a food, beverage, or pharmaceutical.
- FIG. 1 shows the change in DHNA concentration when the switching time to air rate is changed.
- FIG. 2 shows the change in lactose concentration when the switching time to air rate is changed.
- FIG. 3 shows the timing of switching to the air rate and changes in the number of propionic acid bacteria.
- FIG. 4 shows the concentration of propionic acid when the switching time to the air rate is changed.
- FIG. 5 shows the acetic acid concentration when the switching time to the air rate is changed.
- FIG. 6 shows the DHNA concentration when the flow rate of the air rate was changed.
- the propionic acid bacterium used in the production method of the present invention is not particularly limited as long as it is a DHNA-producing bacterium, and a bacterium belonging to the genus Propio-bataterum is preferred.
- a bacterium belonging to the genus Propio-bataterum is preferred.
- propioninobacterium ' freudenreichii Propio-bacterium 'Tenny (P. thoenii), Propio-batatherimu' P. acidipropionici (P. acidipropionici) ', Propio-batatherimu' P. jensenii '
- Examples include butterium 'Avidum' (P. avidum), propio-bataterum 'Aknes (P.
- P. freudenreich ii IFO 12424 P. freudenreichii ATCC 6207, and P. freudenreichii ET-3 (FERM P-18454) are particularly preferred!
- the medium used in the method of the present invention is preferably a medium containing a carbon source.
- the carbon source refers to a carbon source that can be assimilated by propionic acid bacteria.
- lactose glucose, lactic acid, glycerol, dartene, cellulose and the like can be mentioned, and lactose is particularly preferred.
- the content of the carbon source in the medium before the start of the culture is preferably 418% by mass, more preferably 417% by mass, and particularly preferably 417% by mass.
- a medium containing lactose as a carbon source includes whey powder, power zein, skim milk powder, or whey protein concentration obtained by dialyzing whey to reduce the lactose content.
- a whey protein isolate obtained by further separating the lactose content from the condensate or the lactose content may be mentioned. These can be used as they are or after being treated with protease, and can be used as a carbon source that can be used as a carbon source for assimilating peptone such as yeast extract and trypticase, and propionic acid bacteria such as glucose, lactose, and lactase-treated lactase.
- the medium can be prepared by adding the medium.
- the following is an example of a method for preparing a medium containing a protease-treated skim milk powder as a medium material.
- the skim milk powder is dissolved in water so as to have a concentration of 10 to 20% by mass, and the temperature is adjusted to 47 ° C.
- protease is added at 2.5% by mass of the skim milk powder to decompose the protein in the skim milk solution.
- the protease include proteolytic enzymes derived from animals and plants or bacteria, and can be used regardless of acidity, neutrality, or alkalinity.
- the digestion is performed for 6 hours, the temperature during the digestion is adjusted to 47 ° C and the pH is adjusted to 6.8. To adjust the pH, use a potassium carbonate aqueous solution. When the decomposition by the protease is completed, the skim milk solution is heated to 80 ° C.
- Sterilization conditions are 7 minutes or more at 121 ° C when using an autoclave, and 4 seconds or more at 140 ° C or more when a sterile plate is used.
- the culture medium thus obtained usually contains lactose in an amount of 45% by mass.
- the culture is performed under anaerobic conditions.
- the anaerobic condition can be, for example, one or a combination of two or more of nitrogen gas, helium gas, argon gas, hydrogen gas, and other inert gas. . More specifically, nitrogen gas, carbon dioxide gas, etc. are flowed through the top of the fermenter by aeration on the top surface, stirring is performed, and the medium temperature is adjusted to 33 ° C. When the medium temperature is stabilized at 33 ° C, inoculate a starter for propionic acid bacteria and start cultivation under anaerobic conditions. As the starter, an activated culture solution of propionic acid bacteria, a cell concentrate of the culture solution, and the like can be used.
- the amount to be added to the medium is about 0.05% of the medium in the former case, and about 0.3% in the latter case as a guideline.These amounts can be changed even if necessary as needed. .
- Culture is performed under the conditions of a culture temperature of 20 to 40 ° C and a medium pH of neutral to slightly acidic (preferably pH 5.5 to 7.5).
- a known neutralizing agent such as an aqueous solution of potassium carbonate or an aqueous solution of sodium carbonate can be used.
- the time when the air rate is started is when the carbon source concentration in the culture medium becomes 3.5% by mass or less.
- One guideline is 24 hours before the carbon source of the propionic acid bacterium dies. You. It is more preferable to start the aeration when the carbon source concentration reaches 1.0 to 3.5% by mass, particularly 1.5 to 3.0% by mass.
- propionic acid bacteria By aeration when the carbon source concentration falls below 3.5% by mass, propionic acid bacteria also consume cacaine and propionic acid as a carbon source, and eventually the carbon source almost depletes. .
- the number of propionic acid bacteria in the culture medium at the start of aeration should be 1.OX 10 1G cfu / mL (10.0 log cfu / mL) or more, and 1.4 X 10 1G cfuZmL (10.1 log cfuZmL) or more. preferable. By doing so, the carbon source in the medium can be almost depleted. In the above-mentioned lactose-containing medium and culture conditions, about 48 hours after the start of the culture, the lactose concentration becomes 3.5% by mass or less, and it is time to start the aeration.
- the amount of air supplied by the air rate is preferably an amount that stimulates propionic acid bacteria.
- a specific example on a laboratory scale (1.5 L capacity) is as follows.
- the air supply rate is 2 L or more for Z minutes.
- the amount is preferably 2 LZ minutes to 4 LZ minutes, but can be appropriately adjusted according to the capacity, stirring speed, apparatus and the like. If the amount of dissolved oxygen in the solution becomes unnecessarily high, growth of propionic acid bacteria is stopped, and DHNA production is stopped. Round.
- the culture is usually completed in about 168 hours from the start of the culture.
- Examples of the method of aeration include a method of inserting a porous ventilation tube into a culture medium and sending air over the entire surface of the tube, and a method of sending bubbles using a sparger.
- the DHNA accumulated in the medium and the cells can be stopped for culturing and immediately used for DHNA collection from the culture.
- the end point of the culture is about 3 to 5 days when the number of bacteria reaches the stationary phase and the carbon source in the medium dies.
- the culture may be the culture after the above-described aeration, or may be the culture after the completion of the culture under ordinary anaerobic or microaerobic conditions without passing through the aeration.
- the amount of the carbon source added to the culture is such that the carbon source concentration in the culture is 0.2 to 3.0% by mass, more preferably 0.4 to 2.5% by mass, particularly 0.8 to 2%. It is preferable to set the amount to 2% by mass.
- a base such as potassium carbonate, sodium carbonate or sodium phosphate to adjust the pH of the culture to 7-9, especially 7.5-8.5. Is preferred.
- the storage temperature is 3-20 ° C, particularly 3-15 ° C, and more preferably 5-15 ° C.
- the storage period is preferably 1 to 3 weeks, particularly preferably 1 to 2 weeks.
- the obtained culture is preferably subjected to adsorption chromatography.
- a reversed-phase adsorbent such as activated carbon or a synthetic adsorbent (for example, Diaion HP-20, manufactured by Mitsubishi Iridaku Co., Ltd.) can be widely used.
- the column is filled with the adsorbent and washed with 0.5% (wZv) sodium ascorbate aqueous solution.
- the obtained culture is added to a column (the passing solution is referred to as "pass"), and the water-soluble fraction is removed with a 0.5% (wZv) aqueous sodium ascorbate solution.
- Examples of DHNA salts include pharmaceutically or food acceptable salts.
- Representative salts include monovalent metal salts such as sodium, potassium, and lithium, and magnesium, calcium, and zinc. Examples thereof include polyvalent metal salts, and inorganic or organic amine salts such as ammonia and ethanolamine.
- salt exchange can also be performed by using a reaction known per se.
- the salt examples include salts with inorganic acids (eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid) and organic acids (eg, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citrate) And malic acid, oxalic acid, benzoic acid, methanesulfonic acid and benzenesulfonic acid), but these are only examples, and the present invention is not limited to these salts.
- inorganic acids eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid
- organic acids eg, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citrate
- malic acid oxalic acid
- benzoic acid methanesulfonic acid and benzenesulfonic acid
- DHNA is contained in the culture of the DHNA-producing bacteria (inside and inside or outside of the cells), the culture itself is used without application of adsorption chromatography using a rotary evaporator or the like.
- a composition containing a high concentration of DHNA can be obtained. It is also preferable to separate the cells from the culture by a usual centrifugation method and concentrate the supernatant.
- the composition thus obtained may be used in a liquid state or may be processed into a powder according to the form to be used.
- the DHNA-containing composition obtained by force exerts a high DHNA concentration, suppresses bitterness, and has a good flavor. Therefore, the DHNA-containing composition of the present invention, or DHNA or a salt thereof, can be used in the form of a food or drink or a medicament, for example, by directly administering it as a medicament, or special food such as food for specified health use. By ingesting directly as intended foods or functional foods, or by adding various foods (milk, soft drinks, fermented milk, 1 dart, cheese, bread, biscuit, cracker, pizza crust, etc.), and ingesting it can improve intestinal flora and reduce abdominal discomfort seen when consuming milk. It can prevent and treat metabolic bone disease.
- water, protein, saccharide, lipid, vitamin, and minerals, organic acid, fruit juice, flavor, and the like can be combined as main components.
- whole milk powder, skim milk powder, partially skim milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, ⁇ -casein, ⁇ -casein, ⁇ -latatoglobulin, and lactalbumin Animal and plant proteins such as ratatoferrin, soy protein, chicken egg protein, meat protein, etc., and their various hydrolysates, butter, whey minerals, cream, whey, non-protein nitrogen, sialic acid, phospholipids, lactose, etc.
- Animal oils such as fish oil; palm oil, safflower oil, corn oil, Vegetable oils and fats such as seed oil and coconut oil, their fractionated oils, hydrogenated oils, and vegetable oils such as transesterified oils; vitamin ⁇ , vitamin ⁇ , vitamin C, erythorbic acid, vitamin D, vitamin E,
- vitamins such as vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, piotin, inosit, choline, folic acid; calcium, potassium, magnesium, sodium, chlorine, copper, iron, manganese, zinc, Minerals such as selenium, fluorine, silicon, and iodine; organic acids and organic acids
- Liquid, solid (including granules, powders, tablets, and gels) and semi-solids It may be in any form (including jelly), paste, emulsified, and the like.
- composition according to the present invention or DHNA or a salt thereof When used as a pharmaceutical, it can be administered in various forms. Examples of the form include oral administration by tablets, capsules, granules, powders, syrups and the like. These various products
- the agent can be used in the pharmaceutical formulation technical field such as excipients, binders, disintegrants, lubricants, flavors, flavoring agents, solubilizers, suspending agents, coating agents, etc. in the main agent according to the usual method. It can be formulated using known auxiliaries.
- the quantification of DHNA was performed according to the method described on page 9 of WO03Z016544.
- the lactose concentration was measured by a flow injection analysis method using a lactose electrode (using a flow injection analyzer, Bio Flow Analyzer (trade name) manufactured by Oji Scientific Instruments).
- the number of propionic acid bacteria was measured on a BL agar medium.
- the concentrations of propionic acid and acetic acid were measured by an HPLC method (column: RS pa k KC-811 + pre-column KCG, detection: UV445 nm).
- skim milk powder manufactured by Meiji Dairies Co., Ltd.
- 100 g of water 150 g was dissolved in 100 g of water, and the temperature was adjusted to 47 ° C.
- protease was added, and protein degradation was performed at 47 ° C for 6 hours.
- the pH during protein degradation was adjusted to 6.6-6.8 using potassium carbonate solution.
- the protease was inactivated by heating to 80 ° C and holding for 10 minutes, 7.5 g of brewer's yeast extract was added, and the pH was adjusted to 6.95 using an aqueous potassium carbonate solution.
- the volume of the solution was adjusted to 1500 mL with water, and the solution was placed in a 2 L fermenter to sterilize the medium. Sterilization conditions were 121 ° C for 7 minutes.
- Nitrogen gas was passed through the fermenter, and the temperature of the medium was stabilized at 33 ° C. Then, 0.75 mL of a freeze concentration starter (P. freudenreichii ET-3) was added, and culture was started. During fermentation, the temperature was adjusted to 33 ° C, the pH was adjusted to 6.5, and nitrogen gas was aerated. The pH was adjusted using a 40% (wtZ wt) aqueous potassium carbonate solution. The following five types of culture methods were implemented.
- skim milk powder manufactured by Meiji Dairies Co., Ltd.
- the protein was decomposed at 47 ° C for 3 hours after adding 3.75g of protease to the mixture.
- ⁇ ⁇ was adjusted using an aqueous potassium carbonate solution at 6.6-6.8.
- the protease was inactivated by heating to 80 ° C and holding for 10 minutes, 7.5 g of beer yeast extract and 15 g of lactose were added, and the pH was adjusted to 6.95 using an aqueous potassium carbonate solution. did.
- the volume of the solution was adjusted to 1500 mL with water, and the solution was placed in a 2 L fermenter, and the medium was sterilized (lactose concentration mass: about 6.1%). Sterilization conditions were 121 ° C for 7 minutes.
- Example 2 The DHNA-containing culture obtained in Example 2 was supplemented with sodium ascorbate (1.0%) and lactose (2.0%), and the pH was adjusted to 8.0. As a result of storage at ° C for 2 weeks, the DHNA concentration was 55 ⁇ gZmL. When lactose was replaced with glucose and stored in the same manner, the DHNA concentration increased from the end of the culture.
- the DHNA-containing culture obtained in Example 1 was added to 120 g of plain yogurt (manufactured by Meiji Dairies Co., Ltd.), and the sensory evaluation of the prepared yogurt is shown in Tables 1 and 2.
- the yogurt to which the DHNA-containing culture obtained by the method of the present invention was added had a sour taste as compared with the conventional method in which the DHNA concentration was high (the DHNA-containing culture obtained in Comparative Example was added to plain yogurt). It was confirmed that no bitterness was felt.
- a culture having a DHNA concentration of 48 gZmL was obtained.
- the lactose concentration 72 hours after the start of the culture was about 3.0% by mass, and the number of propionic acid bacteria was 2.9 ⁇ 10 1 G cfu / mL.
- the DHNA-containing culture obtained in Example 5 was added with 1.0% sodium ascorbate and 1.0% lactose to adjust the pH to 8.0, and then adjusted to 10 ° C. As a result of storage for 2 weeks, the DHNA concentration was 60 ⁇ g ZmL.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
明 細 書 Specification
1, 4ージヒドロキシー 2—ナフトェ酸の製造法 Preparation of 1,4-dihydroxy-2-naphthoic acid
技術分野 Technical field
[0001] 本発明は、プロピオン酸菌発酵を用いた 1, 4ージヒドロキシー 2—ナフトェ酸 (以下 D HNAとも 、う)の高濃度製造法とその培養物の風味改善技術に関する。 The present invention relates to a method for producing 1,4-dihydroxy-2-naphthoic acid (hereinafter also referred to as DHNA) at a high concentration using fermentation of propionic acid bacteria, and a technique for improving the flavor of a culture thereof.
背景技術 Background art
[0002] DHNAは、従来、染料、顔料及び感光材料として工業材料として有用であることが 知られており、これまでにも有機化学合成法により種々の合成法が開発されている。 本発明者らは、これらに変わる DHNAの製造法について検討した結果、プロピオン 酸菌により菌体内外に大量に産生されることを見出すと共に、この培養物から採取し た DHNA含有組成物、又は 1, 4—ジヒドロキシー 2—ナフトェ酸もしくはその塩には、 乳糖不耐症の牛乳の摂取時にみられる腹部不快症状を低減する作用を有すること、 代謝性骨疾患の予防治療に有用であることを見出した (特許文献 1)。本法により、 D HNAを飲食品や医薬品に用いることを可能にした力 DHNA含有組成物は、風味 の点で必ずしも満足のゆくものではなぐ商品に多用することが困難であった。 [0002] DHNA has conventionally been known to be useful as an industrial material as a dye, a pigment, and a photosensitive material, and various synthetic methods have been developed by organic chemical synthesis methods. The present inventors studied alternative DHNA production methods and found that DHNA was produced in large quantities in and out of the cells by propionic acid bacteria, and the DHNA-containing composition collected from this culture, or 1 , 4-Dihydroxy-2-naphthoic acid or its salt has the effect of reducing the abdominal discomfort seen when ingesting milk with lactose intolerance, and that it is useful for the prevention and treatment of metabolic bone disease (Patent Document 1). According to this method, it has been difficult to use DHNA-containing compositions, which make it possible to use DHNA in foods and drinks and pharmaceuticals, in products that are not always satisfactory in terms of flavor.
特許文献 1:国際公開第 WO03Z016544号パンフレット Patent Document 1: International Publication No. WO03Z016544 pamphlet
発明の開示 Disclosure of the invention
発明が解決しょうとする課題 Problems to be solved by the invention
[0003] 本発明の目的はプロピオン酸菌発酵による風味の改善された DHNA含有組成物 の効率的な製造方法を提供することにある。 [0003] It is an object of the present invention to provide a method for efficiently producing a DHNA-containing composition having improved flavor by propionic acid bacteria fermentation.
課題を解決するための手段 Means for solving the problem
[0004] 本発明者は、苦みの抑制された DHNA含有組成物を得るために各方面から鋭意 検討した結果、全く意外にも、プロピオン酸菌発酵中の一定の時期に培地のエアレ ーシヨンを行うことで、培養物中の DHNA濃度が高まるという有用な新知見を得た。 また、培養後の培養物にプロピオン酸菌の炭素源を添加し、弱アルカリ条件下低温 保存することによつても、培養が終了しているにもかかわらず、 DHNA濃度が高まる ことを見出した。さらに、力べして得られた DHNA含有組成物は苦みが抑制され、風 味が良好であり飲食品や医薬品として有用であることを見出した。 [0004] The present inventors have conducted intensive studies from various angles to obtain a DHNA-containing composition with reduced bitterness. As a result, the culture medium was air-ventilated at a certain time during fermentation of propionic acid bacteria. This led to a useful new finding that the concentration of DHNA in the culture was increased. It was also found that the DHNA concentration was increased by adding a carbon source of propionic acid bacteria to the culture after culturing and storing at low temperature under weak alkaline conditions, even though the culturing was completed. . In addition, the DHNA-containing composition obtained by brute force suppresses bitterness, It was found that the taste was good and that it was useful as a food or drink or pharmaceutical.
すなわち、本発明は、プロピオン酸菌に属する 1, 4ージヒドロキシー 2 ナフトェ酸生 産菌を嫌気的条件下で培養を開始し、培地中の炭素源濃度が 3. 5質量%以下にな つた時点で培地にエアレーシヨンして培養することを特徴とする 1, 4ージヒドロキシー 2 ナフトェ酸の製造法を提供するものである。 That is, according to the present invention, the cultivation of 1,4-dihydroxy-2 naphthoic acid-producing bacteria belonging to the propionic acid bacterium was started under anaerobic conditions, and when the carbon source concentration in the medium became 3.5% by mass or less. An object of the present invention is to provide a method for producing 1,4-dihydroxy-2 naphthoic acid, which comprises culturing by aeration in a medium.
また、本発明は、プロピオン酸菌に属する 1, 4ージヒドロキシー 2 ナフトェ酸生産菌 を嫌気的条件下で培養し、得られた培養物に炭素源を添加し、弱アルカリ下で 3—2 0°Cに保存することを特徴とする 1, 4ージヒドロキシー 2 ナフトェ酸の製造法を提供す るものである。 Also, the present invention provides a method for culturing a 1,4-dihydroxy-2 naphthoic acid-producing bacterium belonging to a propionic acid bacterium under anaerobic conditions, adding a carbon source to the obtained culture, and culturing the solution at a temperature of 3 to 20 ° under a weak alkali. The present invention provides a method for producing 1,4-dihydroxy-2 naphthoic acid, which is stored in C.
また、本発明は、プロピオン酸菌に属する 1, 4ージヒドロキシー 2 ナフトェ酸生産菌 を嫌気的条件下で培養を開始し、培地中の炭素源濃度が 3. 5質量%以下になつた 時点で培地にエアレーシヨンして培養し、得られた培養物に炭素源を添加し、弱アル カリ条件下で 3— 20°Cに保存することを特徴とする 1, 4ージヒドロキシー 2 ナフトェ酸 の製造法を提供するものである。 Further, the present invention provides a method for culturing a 1,4-dihydroxy-2 naphthoic acid-producing bacterium belonging to a propionic acid bacterium under an anaerobic condition, and when the carbon source concentration in the medium becomes 3.5% by mass or less, A method for producing 1,4-dihydroxy-2 naphthoic acid, characterized in that the culture is obtained by aeration, and a carbon source is added to the resulting culture and stored at 3-20 ° C under weak alkaline conditions. Is what you do.
また、本発明は前記の如くして得られた 1, 4ージヒドロキシー 2 ナフトェ酸含有組成 物を提供するものである。 The present invention also provides a 1,4-dihydroxy-2 naphthoic acid-containing composition obtained as described above.
また、本発明は前記の如くして得られた 1, 4ージヒドロキシー 2 ナフトェ酸含有組成 物を有効成分として含有する腹部不快症状改善用飲食品、腹部不快症状改善剤、 代謝性骨疾患予防治療用飲食品又は代謝性骨疾患予防治療剤を提供するもので ある。 Further, the present invention provides a food and beverage for improving abdominal discomfort symptoms, an agent for improving abdominal discomfort symptoms, an agent for preventing and treating metabolic bone diseases, which comprises the 1,4-dihydroxy-2 naphthoic acid-containing composition obtained as described above as an active ingredient. It is intended to provide a food or drink or an agent for preventing or treating metabolic bone disease.
また、本発明は前記の如くして得られた 1, 4ージヒドロキシー 2 ナフトェ酸含有組成 物の腹部不快症状改善用飲食品、腹部不快症状改善剤、代謝性骨疾患予防治療 用飲食品又は代謝性骨疾患予防治療剤の製造のための使用を提供するものである さらにまた、本発明は前記の如くして得られた 1, 4ージヒドロキシー 2 ナフトェ酸含 有組成物の有効量を投与することを特徴とする腹部不快症状の処置方法又は代謝 性骨疾患の処置方法を提供するものである。 The present invention also relates to a food and drink for improving abdominal discomfort symptoms, an agent for improving abdominal discomfort symptoms, a food and drink for preventing and treating metabolic bone disease, or a metabolic food or drink, of the 1,4-dihydroxy-2 naphthoic acid-containing composition obtained as described above. The present invention also provides use of the composition for the prevention and treatment of bone diseases.The present invention also provides administration of an effective amount of the 1,4-dihydroxy-2 naphthoic acid-containing composition obtained as described above. It is intended to provide a method for treating abdominal discomfort or a method for treating metabolic bone disease.
発明の効果 [0006] 本発明によれば、 DHNAが効率良く生産でき、かつ得られた DHNA含有組成物 は風味が良好で飲食品、医薬品として有用である。 The invention's effect [0006] According to the present invention, DHNA can be produced efficiently, and the obtained DHNA-containing composition has a good flavor and is useful as a food, beverage, or pharmaceutical.
図面の簡単な説明 Brief Description of Drawings
[0007] [図 1]エアレーシヨンへの切替え時期を変化させた場合の DHNA濃度の変化を示す [0007] [Fig. 1] shows the change in DHNA concentration when the switching time to air rate is changed.
[図 2]エアレーシヨンへの切替え時期を変化させた場合の乳糖濃度の変化を示す。 FIG. 2 shows the change in lactose concentration when the switching time to air rate is changed.
[図 3]エアレーシヨンへの切替え時期とプロピオン酸菌数の変化を示す。 FIG. 3 shows the timing of switching to the air rate and changes in the number of propionic acid bacteria.
[図 4]エアレーシヨンへの切替え時期を変化させた場合のプロピオン酸濃度を示す。 FIG. 4 shows the concentration of propionic acid when the switching time to the air rate is changed.
[図 5]エアレーシヨンへの切替え時期を変化させた場合の酢酸濃度を示す。 FIG. 5 shows the acetic acid concentration when the switching time to the air rate is changed.
[図 6]エアレーシヨンの流量を変化させた場合の DHNA濃度を示す。 FIG. 6 shows the DHNA concentration when the flow rate of the air rate was changed.
発明を実施するための最良の形態 BEST MODE FOR CARRYING OUT THE INVENTION
[0008] 本発明の製造法に用いられるプロピオン酸菌としては、 DHNA産生菌であれば特 に限定されないが、プロピオ-バタテリゥム属に属する菌が好ましぐ例えばプロピオ ニノ クテリゥム 'フロイテンライヒ (Propionibacterium freudenreichii)、プロピオ -バクテリゥム 'トェニー(P. thoenii)、プロピオ-バタテリゥム 'ァシディプロピオ-シ (P. acidipropionici)、プロピオ-バタテリゥム'ジェンセ-ー(P. jensenii)などのチ ーズ用の菌、プロピオ-バタテリゥム 'アビダム(P. avidum)、プロピオ-バタテリゥム 'ァクネス(P. acnes)、プロピオ-バタテリゥム 'リンホフイラム(P. lymphophilum)、 プロピオ-バタテリゥム'ダラ-ュロサム(P. granulosam)などを挙げることができる。 このうち、プロピオ-バタテリゥム 'フロイデンライヒが好ましぐさらに P. freudenreich ii IFO 12424及び P. freudenreichii ATCC 6207、 P. freudenreichii ET —3 (FERM P— 18454)が特に好まし!/ヽ。 [0008] The propionic acid bacterium used in the production method of the present invention is not particularly limited as long as it is a DHNA-producing bacterium, and a bacterium belonging to the genus Propio-bataterum is preferred. For example, propioninobacterium ' freudenreichii), Propio-bacterium 'Tenny (P. thoenii), Propio-batatherimu' P. acidipropionici (P. acidipropionici) ', Propio-batatherimu' P. jensenii ' Examples include butterium 'Avidum' (P. avidum), propio-bataterum 'Aknes (P. acnes), propio-batateurium' Linphofilum (P. lymphophilum), propio-bataterimu 'dala-urosum (P. granulosam) and the like. Of these, P. freudenreich ii IFO 12424, P. freudenreichii ATCC 6207, and P. freudenreichii ET-3 (FERM P-18454) are particularly preferred!
[0009] 本発明方法に用いる培地は、炭素源を含有する培地が好ましぐ本発明における 炭素源とは、プロピオン酸菌が資化できる炭素源をいう。例えば乳糖、ブドウ糖、乳酸 、グリセロール、ダルテン、セルロース等が挙げられ、特に乳糖が好ましい。培養開始 前の培地中の炭素源含有量は 4一 8質量%、さらに 4一 7質量%、特に 4一 6. 7質量 %が好ましい。このうち、炭素源として乳糖を含有させた培地としては、ホエイ粉、力 ゼイン、脱脂粉乳、或いはホエイを透析処理して乳糖含量を減らしたホエイ蛋白質濃 縮物、或いは乳糖含量を更に高純度に分離したホエイ蛋白質分離物が挙げられる。 これらはそのまま、或いはプロテアーゼ処理して用いることも可能であり、酵母エキス 、トリプチケース等のペプトンと、ブドウ糖、乳糖、乳糖のラタターゼ処理物等プロピオ ン酸菌が資化する炭素源となり得る単糖類及び Z又は 2糖類等の適量の糖類と、乳 酸、グリセロール、ダルテン、セルロース、乳清ミネラル等のミネラル分、必要に応じて 牡蠣、生姜等ミネラル分を多く含む動植物性食品又はその抽出物を添加することに より培地を調製することができる。以下に、培地原料に脱脂粉乳のプロテアーゼ処理 物を主成分とする培地調製法の一例を示す。 [0009] The medium used in the method of the present invention is preferably a medium containing a carbon source. In the present invention, the carbon source refers to a carbon source that can be assimilated by propionic acid bacteria. For example, lactose, glucose, lactic acid, glycerol, dartene, cellulose and the like can be mentioned, and lactose is particularly preferred. The content of the carbon source in the medium before the start of the culture is preferably 418% by mass, more preferably 417% by mass, and particularly preferably 417% by mass. Among these, a medium containing lactose as a carbon source includes whey powder, power zein, skim milk powder, or whey protein concentration obtained by dialyzing whey to reduce the lactose content. A whey protein isolate obtained by further separating the lactose content from the condensate or the lactose content may be mentioned. These can be used as they are or after being treated with protease, and can be used as a carbon source that can be used as a carbon source for assimilating peptone such as yeast extract and trypticase, and propionic acid bacteria such as glucose, lactose, and lactase-treated lactase. Animal and plant foods or extracts thereof containing a suitable amount of saccharides such as saccharides and Z or disaccharides, and minerals such as lactate, glycerol, dartene, cellulose, whey minerals, and, if necessary, oysters and ginger. The medium can be prepared by adding the medium. The following is an example of a method for preparing a medium containing a protease-treated skim milk powder as a medium material.
[0010] 脱脂粉乳を 10— 20質量%になるように水で溶解し、温度を 47°Cに調整する。これ にプロテアーゼを脱脂粉乳量の 2. 5質量%を添加し、脱脂粉乳溶液中のタンパク質 を分解する。プロテアーゼとしては、動植物由来又は細菌由来のタンパク質分解酵 素が挙げられ、酸性、中性、アルカリ性を問わず使用することができる。分解は 6時間 行い、分解中の温度は 47°C、 pHは 6. 8に調整する。 pHの調整には炭酸カリウム水 溶液を用いる。プロテアーゼによる分解が終了したら脱脂粉乳溶液を 80°Cに加温し 、 10分間保持することでプロテアーゼを失活させる。失活後に脱脂粉乳の質量濃度 が 10%となるように水でメスアップし、脱脂粉乳の 1一 10質量%、好適には 3— 7質 量%のビール酵母エキスを添加した後、滅菌する。滅菌条件はオートクレープを用い る場合が 121°Cで 7分以上、滅菌プレートを用いる場合が 140°C以上で 4秒以上とす る。こうして得られた培地中には通常 4一 5質量%の乳糖が含まれている。 [0010] The skim milk powder is dissolved in water so as to have a concentration of 10 to 20% by mass, and the temperature is adjusted to 47 ° C. To this, protease is added at 2.5% by mass of the skim milk powder to decompose the protein in the skim milk solution. Examples of the protease include proteolytic enzymes derived from animals and plants or bacteria, and can be used regardless of acidity, neutrality, or alkalinity. The digestion is performed for 6 hours, the temperature during the digestion is adjusted to 47 ° C and the pH is adjusted to 6.8. To adjust the pH, use a potassium carbonate aqueous solution. When the decomposition by the protease is completed, the skim milk solution is heated to 80 ° C. and kept for 10 minutes to inactivate the protease. After inactivation, mess up with water so that the mass concentration of skim milk powder becomes 10%, add brewer's yeast extract of 110 to 10 mass%, preferably 3 to 7 mass% of skim milk powder, and sterilize. . Sterilization conditions are 7 minutes or more at 121 ° C when using an autoclave, and 4 seconds or more at 140 ° C or more when a sterile plate is used. The culture medium thus obtained usually contains lactose in an amount of 45% by mass.
[0011] 培養は、嫌気的条件下で行われる。嫌気的条件は、例えば窒素ガス、ヘリウムガス 、アルゴンガス、水素ガス、その他不活性ガスを 1種又は 2種以上組み合わせることが 可能で、中でも窒素ガス又は炭酸ガス雰囲気下の条件とするのが好ましい。より具体 的には、フアーメンター中に窒素ガス、炭酸ガス等を上面通気で流し、撹拌を行い、 培地温度を 33°Cに調整する。培地温度が 33°Cで安定したら、プロピオン酸菌スター ターを接種して嫌気的条件下培養を開始する。スターターには、プロピオン酸菌の賦 活培養液や、培養液の菌体濃縮物などが利用可能である。培地への添加量は、前 者の場合培地に対して 0. 05%、後者の場合 0. 3%程度が目安となる力 これらの 量は必要に応じて適宜変更しても力まわな 、。 [0012] 培養温度は、 20— 40°C、培地の pHは中性ー微酸性 (好ましくは pH5. 5-7. 5) の条件下で培養する。培養中の酸度上昇を抑制するには、炭酸カリウム水溶液、炭 酸ナトリウム水溶液等、中和剤として知られている公知のものを使用することができる [0011] The culture is performed under anaerobic conditions. The anaerobic condition can be, for example, one or a combination of two or more of nitrogen gas, helium gas, argon gas, hydrogen gas, and other inert gas. . More specifically, nitrogen gas, carbon dioxide gas, etc. are flowed through the top of the fermenter by aeration on the top surface, stirring is performed, and the medium temperature is adjusted to 33 ° C. When the medium temperature is stabilized at 33 ° C, inoculate a starter for propionic acid bacteria and start cultivation under anaerobic conditions. As the starter, an activated culture solution of propionic acid bacteria, a cell concentrate of the culture solution, and the like can be used. The amount to be added to the medium is about 0.05% of the medium in the former case, and about 0.3% in the latter case as a guideline.These amounts can be changed even if necessary as needed. . [0012] Culture is performed under the conditions of a culture temperature of 20 to 40 ° C and a medium pH of neutral to slightly acidic (preferably pH 5.5 to 7.5). In order to suppress the increase in the acidity during the culture, a known neutralizing agent such as an aqueous solution of potassium carbonate or an aqueous solution of sodium carbonate can be used.
[0013] 次に培地にエアレーシヨンする方法について説明する。この手段により DHNAの 生産量が増大することは、驚くべきことである。エアレーシヨンを継続的に行うことによ り DHNAの生産量が増大する理由は明らかではないが、このエアレーシヨンによって 、プロピオン酸菌がプロピオン酸の消費を開始する。 Next, a method of aerating the culture medium will be described. It is surprising that this measure increases DHNA production. It is not clear why the continuous aeration increases DHNA production, but this aeration causes propionic acid bacteria to begin consuming propionic acid.
[0014] エアレーシヨンを開始する時期は、培地中の炭素源濃度が 3. 5質量%以下になつ た時点であるが、プロピオン酸菌の炭素源が枯渴する 24時間前が一つの目安にな る。エアレーシヨン開始時期は、さらに、炭素源濃度が 1. 0-3. 5質量%となった時 点、特に 1. 5-3. 0質量%となった時点がより好ましい。炭素源濃度が 3. 5質量% 以下になった時点でエアレーシヨンすることでプロピオン酸菌は、炭素源にカ卩ぇプロ ピオン酸も消費するようになり、最終的に炭素源はほぼ枯渴する。エアレーシヨン開 始時の培地中のプロピオン酸菌数は、 1. O X 101Gcfu/mL (10. 0 log cfu/mL )以上、さらに 1. 4 X 101GcfuZmL (10. 1 log cfuZmL)以上が好ましい。こうす ることにより、培地中の炭素源をほぼ枯渴させることができる。前述の乳糖含有培地 及び培養条件では、培養開始後約 48時間後に、乳糖濃度が 3. 5質量%以下になり 、エアレーシヨン開始時期となる。なお、乳糖、ブドウ糖といったプロピオン酸菌の炭 素源となる糖類を途中添加する培養法も知られているが (例えば特許文献 1、特開平 10— 304871号公報)、本発明においては、これら糖類を途中添カ卩はせず枯渴させ ることが好ましい。 [0014] The time when the air rate is started is when the carbon source concentration in the culture medium becomes 3.5% by mass or less. One guideline is 24 hours before the carbon source of the propionic acid bacterium dies. You. It is more preferable to start the aeration when the carbon source concentration reaches 1.0 to 3.5% by mass, particularly 1.5 to 3.0% by mass. By aeration when the carbon source concentration falls below 3.5% by mass, propionic acid bacteria also consume cacaine and propionic acid as a carbon source, and eventually the carbon source almost depletes. . The number of propionic acid bacteria in the culture medium at the start of aeration should be 1.OX 10 1G cfu / mL (10.0 log cfu / mL) or more, and 1.4 X 10 1G cfuZmL (10.1 log cfuZmL) or more. preferable. By doing so, the carbon source in the medium can be almost depleted. In the above-mentioned lactose-containing medium and culture conditions, about 48 hours after the start of the culture, the lactose concentration becomes 3.5% by mass or less, and it is time to start the aeration. In addition, a culturing method in which saccharides such as lactose and glucose serving as carbon sources of propionic acid bacteria are added in the middle is known (for example, Patent Document 1, Japanese Patent Application Laid-Open No. 10-304871), but in the present invention, these saccharides are used. It is preferable to let the syrup be dried without adding the soybean curd on the way.
[0015] エアレーシヨンによる空気の供給量としては、プロピオン酸菌に刺激を与える程度 の量が好ましい。この条件に相当する一例としてラボスケール(1. 5L容量)での具体 例を挙げると、スパージヤーを使用し撹拌パネで 150rpmの条件下培養を行う場合、 空気の供給量は 2L以上 Z分、より好ましくは 2LZ分一 4LZ分であるが、容量、撹 拌速度、装置等に合わせ適宜調整することができる。なお、液中の溶存酸素量が必 要以上に高くなつた場合には、プロピオン酸菌の生育が休止し、 DHNAの産生も止 まる。前記の培地及び培養条件の場合、通常培養開始力ゝら約 168時間で培養を終 了する。 [0015] The amount of air supplied by the air rate is preferably an amount that stimulates propionic acid bacteria. As an example corresponding to this condition, a specific example on a laboratory scale (1.5 L capacity) is as follows. When culturing at 150 rpm with a stirring panel using a sparger, the air supply rate is 2 L or more for Z minutes. The amount is preferably 2 LZ minutes to 4 LZ minutes, but can be appropriately adjusted according to the capacity, stirring speed, apparatus and the like. If the amount of dissolved oxygen in the solution becomes unnecessarily high, growth of propionic acid bacteria is stopped, and DHNA production is stopped. Round. In the case of the above-mentioned medium and culture conditions, the culture is usually completed in about 168 hours from the start of the culture.
[0016] エアレーシヨンの方法としては、培地に多孔性の通気チューブを挿入して、チュー ブ全面で空気を送り込む方法や、スパージヤーで気泡を送り込む方法が挙げられる [0016] Examples of the method of aeration include a method of inserting a porous ventilation tube into a culture medium and sending air over the entire surface of the tube, and a method of sending bubbles using a sparger.
[0017] このようにして、培地及び菌体に蓄積された DHNAは、培養を停止し、直ちにその 培養物より DHNAの採取に供することができる。また、培養の終点としては、菌数が 定常期に達し、培地中の炭素源が枯渴して力 3— 5日が目安となる。 [0017] In this way, the DHNA accumulated in the medium and the cells can be stopped for culturing and immediately used for DHNA collection from the culture. In addition, the end point of the culture is about 3 to 5 days when the number of bacteria reaches the stationary phase and the carbon source in the medium dies.
[0018] 次に、培養終了後の培養物にプロピオン酸菌の炭素源を添加し、弱アルカリ下で 3 一 20°Cに保存して DHNAを製造する方法について説明する。ここで培養物は、前 記のエアレーシヨン後の培養物でもよいが、エアレーシヨンを経由しない通常の嫌気 的又は微好気的条件下による培養終了後の培養物でもよい。 Next, a method for producing DHNA by adding a carbon source of propionibacteria to a culture after completion of the culture and storing the culture at 321 ° C. under a weak alkali will be described. Here, the culture may be the culture after the above-described aeration, or may be the culture after the completion of the culture under ordinary anaerobic or microaerobic conditions without passing through the aeration.
[0019] 培養物への炭素源添加量は、培養物中の炭素源濃度が 0. 2-3. 0質量%、さら に 0. 4-2. 5質量%、特に 0. 8-2. 2質量%となるよう設定することが好ましい。ま た、弱アルカリ下にするには、炭酸カリウム、炭酸ナトリウム、リン酸ナトリウム等の塩基 を添カ卩して培養物の pHが 7— 9、特に 7. 5-8. 5になるようにするのが好ましい。ま た、保存温度は 3— 20°C、特に 3— 15°C、さらに 5— 15°Cが好ましい。保存期間は、 1一 3週間、特に 1一 2週間が好ましい。 [0019] The amount of the carbon source added to the culture is such that the carbon source concentration in the culture is 0.2 to 3.0% by mass, more preferably 0.4 to 2.5% by mass, particularly 0.8 to 2%. It is preferable to set the amount to 2% by mass. To make the culture weakly alkaline, add a base such as potassium carbonate, sodium carbonate or sodium phosphate to adjust the pH of the culture to 7-9, especially 7.5-8.5. Is preferred. Further, the storage temperature is 3-20 ° C, particularly 3-15 ° C, and more preferably 5-15 ° C. The storage period is preferably 1 to 3 weeks, particularly preferably 1 to 2 weeks.
[0020] このような弱アルカリ下の低温保存により培養物中の DHNA含量が向上する。こう して、新たな設備を必要とせず、省スペースで、し力も保存中に DHNA量を増大でき る本方法は極めて有用かつ効果的な製造法と!/、える。 [0020] Such low-temperature storage under a weak alkali improves the DHNA content in the culture. Thus, this method, which does not require new equipment, saves space, and can increase the amount of DHNA during storage, is extremely useful and effective!
[0021] 次に、 DHNAの採取方法について説明する。得られた培養物を吸着クロマトグラフ ィ一に付すのが好ましい。吸着剤としては、活性炭や合成吸着剤 (例えばダイアイォ ン HP— 20、三菱ィ匕学 (株)製)などの逆相系の吸着剤を広く使用することができる。ま ず、吸着剤をカラムに充填し、 0. 5% (wZv)ァスコルビン酸ナトリウム水溶液で洗浄 する。次いで、得られた培養物をカラムに添カ卩し (通過液を passとした)、さらに 0. 5 % (wZv)ァスコルビン酸ナトリウム水溶液で水溶性画分を除去する。その後、 0. 5 % (w/v)量ァスコルビン酸ナトリウムを添カ卩したエタノールで溶出し、このエタノール 溶出画分を濃縮することで、 DHNAを高濃度に含む組成物を得ることができる。さら に、精製を行い、純粋な DHNA又はその塩を得ることができる。尚、カラムからの DH NAの溶出液としてエタノールの代わりにメタノール等の他のアルコールを用いてもよ い。また、これに代わる方法として、培養物を遠心分離し回収した上澄み液から、液 体クロマトグラフィーを用いて DHNAを分取することも可能である。なお、ァスコルビ ン酸ナトリウムに代わり、エリソルビン酸ナトリウムを用いることも好ましぐこれらは、 D HNAの安定化剤として用いられる力 本発明では、ァスコルビン酸、エリソルビン酸 、これらの遊離の酸のほカゝ、脂肪酸エステルその他各種のエステル類、アルカリ金属 塩、その他の塩類も同様に使用することができる。 Next, a method of collecting DHNA will be described. The obtained culture is preferably subjected to adsorption chromatography. As the adsorbent, a reversed-phase adsorbent such as activated carbon or a synthetic adsorbent (for example, Diaion HP-20, manufactured by Mitsubishi Iridaku Co., Ltd.) can be widely used. First, the column is filled with the adsorbent and washed with 0.5% (wZv) sodium ascorbate aqueous solution. Next, the obtained culture is added to a column (the passing solution is referred to as "pass"), and the water-soluble fraction is removed with a 0.5% (wZv) aqueous sodium ascorbate solution. After that, 0.5% (w / v) amount of sodium ascorbate was eluted with ethanol added with sodium chloride and this ethanol was added. By concentrating the eluted fraction, a composition containing DHNA at a high concentration can be obtained. Furthermore, purification can be performed to obtain pure DHNA or a salt thereof. Note that another alcohol such as methanol may be used instead of ethanol as the eluate of DHNA from the column. As an alternative, DHNA can be separated from the supernatant obtained by centrifuging the culture and collecting the DHNA using liquid chromatography. In addition, it is also preferable to use sodium erythorbic acid instead of sodium ascorbate. These are useful as stabilizers for DHNA. In the present invention, ascorbic acid, erythorbic acid, and those free acids are mainly used.ゝ, fatty acid esters and other various esters, alkali metal salts and other salts can also be used.
[0022] DHNAの塩としては、薬学的又は食品学的に許容できる塩が挙げられ、代表的な 塩には、ナトリウム、カリウム、リチウム等の一価金属塩、マグネシウム、カルシウム、亜 鉛等の多価金属塩、アンモニア、エタノールァミン等の無機あるいは有機アミン塩等 が挙げられる。また、自体公知の反応を用いることにより、塩交換を行うこともできる。 該塩としては、無機酸 (例えば、塩酸、リン酸、臭気水素酸、硫酸)との塩、あるいは有 機酸(例えば、ギ酸、プロピオン酸、フマル酸、マレイン酸、コハク酸、酒石酸、クェン 酸、リンゴ酸、シユウ酸、安息香酸、メタンスルホン酸、ベンゼンスルホン酸)との塩等 が用いられるが、これらは例示であって、本発明はこれらの塩に限定されない。 [0022] Examples of DHNA salts include pharmaceutically or food acceptable salts. Representative salts include monovalent metal salts such as sodium, potassium, and lithium, and magnesium, calcium, and zinc. Examples thereof include polyvalent metal salts, and inorganic or organic amine salts such as ammonia and ethanolamine. In addition, salt exchange can also be performed by using a reaction known per se. Examples of the salt include salts with inorganic acids (eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid) and organic acids (eg, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citrate) And malic acid, oxalic acid, benzoic acid, methanesulfonic acid and benzenesulfonic acid), but these are only examples, and the present invention is not limited to these salts.
[0023] DHNAは、 DHNA産生菌の培養物中(菌体内及び Z又は外)に含有されて ヽる ので、吸着クロマトグラフィーを適用せずに培養物それ自体をロータリーエバポレータ 一等を使用し、濃縮することによって DHNAを高濃度に含有する組成物を得ること ができる。また、通常の遠心分離法によって培養物から菌体を分離し得られた上清を 濃縮することも好ましい。こうして得られた組成物は、利用する形態にあわせ、液状の まま用いてもよいし、粉末状に加工することもできる。 [0023] Since DHNA is contained in the culture of the DHNA-producing bacteria (inside and inside or outside of the cells), the culture itself is used without application of adsorption chromatography using a rotary evaporator or the like. By concentrating, a composition containing a high concentration of DHNA can be obtained. It is also preferable to separate the cells from the culture by a usual centrifugation method and concentrate the supernatant. The composition thus obtained may be used in a liquid state or may be processed into a powder according to the form to be used.
[0024] 力べして得られた DHNA含有組成物は DHNA濃度が高ぐ苦みが抑制され、風味 が良好である。従って、本発明の DHNA含有組成物、又は DHNAもしくはその塩は 、飲食用又は医薬品いずれの形態でも利用することができ、例えば、医薬品として直 接投与することにより、或いは特定保健用食品等の特別用途食品、栄養機能食品と して直接摂取することにより、あるいはまた、各種食品(牛乳、清涼飲料、発酵乳、ョ 一ダルト、チーズ、パン、ビスケット、クラッカー、ピッツァクラストその他)に添カ卩してお き、これを摂取することによって、腸内フローラの改善や牛乳の摂取時にみられる腹 部不快症状の低減、代謝性骨疾患の予防治療することができる。 [0024] The DHNA-containing composition obtained by force exerts a high DHNA concentration, suppresses bitterness, and has a good flavor. Therefore, the DHNA-containing composition of the present invention, or DHNA or a salt thereof, can be used in the form of a food or drink or a medicament, for example, by directly administering it as a medicament, or special food such as food for specified health use. By ingesting directly as intended foods or functional foods, or by adding various foods (milk, soft drinks, fermented milk, 1 dart, cheese, bread, biscuit, cracker, pizza crust, etc.), and ingesting it can improve intestinal flora and reduce abdominal discomfort seen when consuming milk. It can prevent and treat metabolic bone disease.
[0025] 前記食品を製造するために、主成分として、水やタンパク質、糖質、脂質、ビタミン 及びミネラル類、有機酸、果汁、フレーバー類等を組み合わせることができる。例え ば、全脂粉乳、脱脂粉乳、部分脱脂粉乳、カゼイン、ホエイ粉、ホエイタンパク質、ホ エイタンパク質濃縮物、ホエイタンパク質分離物、 α -カゼイン、 β—カゼイン、 β—ラ タトグロブリン、 ひ ラクトアルブミン、ラタトフエリン、大豆タンパク質、鶏卵タンパク質、 肉タンパク質等の動植物性タンパク質、これら加水分解物、バター、乳清ミネラル、ク リーム、ホエイ、非タンパク態窒素、シアル酸、リン脂質、乳糖等の各種乳由来成分; 蔗糖、ブドウ糖、果糖、糖アルコール類、麦芽糖、オリゴ糖類、化工澱粉 (デキストリン のほか、ソリュブルスターチ、プリティッシュスターチ、酸化澱粉、澱粉エステル、澱粉 エーテル等)、食物繊維等の炭水化物;ラード、魚油などの動物性油脂;パーム油、 サフラワー油、コーン油、ナタネ油、ヤシ油等の植物性油脂、これらの分別油、水添 油、エステル交換油等の植物性油脂;ビタミン Α、ビタミン Β群、ビタミン C、エリソルビ ン酸、ビタミン D群、ビタミン E、ビタミン K群、ビタミン P、ビタミン Q、ナイァシン、ニコ チン酸、パントテン酸、ピオチン、イノシット、コリン、葉酸などの各種ビタミン;カルシゥ ム、カリウム、マグネシウム、ナトリウム、塩素、銅、鉄、マンガン、亜鉛、セレン、フッ素 、ケィ素、ヨウ素等のミネラル;リンゴ酸、クェン酸、乳酸、酒石酸等の有機酸や有機 酸塩などがあげられ、これらから選択される 1種又は 2種以上を適宜選択して添加す ることができる。これら各種成分は合成品の他、必要に応じこれらを多く含む食品で 添加することも望ましい。また、その形態としては、前記食品に限らず、最終製品で活 性が維持されていれば特に限定されることなぐ液状、固形状 (顆粒、粉末、タブレツ ト、ゲル状を含む)、半固形状 (ゼリー状を含む)、ペースト状、乳化状等のいずれでも よい。 [0025] In order to produce the food, water, protein, saccharide, lipid, vitamin, and minerals, organic acid, fruit juice, flavor, and the like can be combined as main components. For example, whole milk powder, skim milk powder, partially skim milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, α-casein, β-casein, β-latatoglobulin, and lactalbumin Animal and plant proteins such as ratatoferrin, soy protein, chicken egg protein, meat protein, etc., and their various hydrolysates, butter, whey minerals, cream, whey, non-protein nitrogen, sialic acid, phospholipids, lactose, etc. Ingredients: sucrose, glucose, fructose, sugar alcohols, maltose, oligosaccharides, modified starch (such as dextrin, soluble starch, pretty starch, oxidized starch, starch ester, starch ether, etc.), and carbohydrates such as dietary fiber; Animal oils such as fish oil; palm oil, safflower oil, corn oil, Vegetable oils and fats such as seed oil and coconut oil, their fractionated oils, hydrogenated oils, and vegetable oils such as transesterified oils; vitamin Α, vitamin Β, vitamin C, erythorbic acid, vitamin D, vitamin E, Various vitamins such as vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, piotin, inosit, choline, folic acid; calcium, potassium, magnesium, sodium, chlorine, copper, iron, manganese, zinc, Minerals such as selenium, fluorine, silicon, and iodine; organic acids and organic acid salts such as malic acid, citric acid, lactic acid, and tartaric acid; and one or more selected from these as appropriate. Can be added. It is desirable to add these various components to foods containing a large amount of these components as well as synthetic products. The form is not limited to the above-mentioned foods, and is not particularly limited as long as the activity is maintained in the final product. Liquid, solid (including granules, powders, tablets, and gels) and semi-solids It may be in any form (including jelly), paste, emulsified, and the like.
[0026] 本発明に係る組成物、又は DHNAもしくはその塩を医薬品として使用する場合に は、種々の形態で投与することができる。その形態として、例えば、錠剤、カプセル剤 、顆粒剤、散剤、シロップ剤等による経口投与をあげることができる。これらの各種製 剤は、常法に従って主剤に賦形剤、結合剤、崩壊剤、滑沢剤、矯味、矯臭剤、溶解 補助剤、懸濁剤、コーティング剤などの医薬の製剤技術分野において通常使用しう る既知の補助剤を用いて製剤化することができる。 When the composition according to the present invention or DHNA or a salt thereof is used as a pharmaceutical, it can be administered in various forms. Examples of the form include oral administration by tablets, capsules, granules, powders, syrups and the like. These various products The agent can be used in the pharmaceutical formulation technical field such as excipients, binders, disintegrants, lubricants, flavors, flavoring agents, solubilizers, suspending agents, coating agents, etc. in the main agent according to the usual method. It can be formulated using known auxiliaries.
実施例 Example
[0027] 以下、試験例、実施例を挙げ本発明を説明するが、本発明はこれにより限定される ものではない。なお、以下の試験例及び実施例において DHNAの定量は WO03Z 016544第 9頁に記載の方法に従って行った。乳糖濃度の測定は、乳糖電極を用い たフローインジェクション分析法 (王子計測機器 (株)製、フローインジェクション分析 装置、 Bio Flow Analyzer (商品名)使用)によって行った。プロピオン酸菌数の測 定は、 BL寒天培地で行った。プロピオン酸、酢酸濃度は、 HPLC法 (カラム: RS pa k KC— 811 +プレカラム KC G、検出: UV445nm)で測定した。 Hereinafter, the present invention will be described with reference to Test Examples and Examples, but the present invention is not limited thereto. In the following Test Examples and Examples, the quantification of DHNA was performed according to the method described on page 9 of WO03Z016544. The lactose concentration was measured by a flow injection analysis method using a lactose electrode (using a flow injection analyzer, Bio Flow Analyzer (trade name) manufactured by Oji Scientific Instruments). The number of propionic acid bacteria was measured on a BL agar medium. The concentrations of propionic acid and acetic acid were measured by an HPLC method (column: RS pa k KC-811 + pre-column KCG, detection: UV445 nm).
[試験例 1]エアレーシヨン切替え時期の検討 [Test Example 1] Examination of air-rate switching timing
(1)培地の調製 (1) Preparation of medium
[0028] 脱脂粉乳(明治乳業 (株)製) 150gを水 lOOOgに溶解し、温度を 47°Cに調整した。 [0028] 150 g of skim milk powder (manufactured by Meiji Dairies Co., Ltd.) was dissolved in 100 g of water, and the temperature was adjusted to 47 ° C.
これにプロテアーゼを 3. 75g添カ卩して 47°Cで 6時間タンパク質の分解を行った。タン ノ ク質分解中の pHは 6. 6-6. 8に炭酸カリウム溶液を用いて調整した。タンパク質 分解後、 80°Cまで加温し 10分保持することでプロテアーゼを失活させ、ビール酵母 エキスを 7. 5g添加し、炭酸カリウム水溶液を用いて pHを 6. 95に調整した。水で溶 液の容量を 1500mLに調整し、 2L容量のフアーメンターに入れ、培地滅菌を行った 。滅菌条件は 121°C、 7分とした。 To this, 3.75 g of protease was added, and protein degradation was performed at 47 ° C for 6 hours. The pH during protein degradation was adjusted to 6.6-6.8 using potassium carbonate solution. After proteolysis, the protease was inactivated by heating to 80 ° C and holding for 10 minutes, 7.5 g of brewer's yeast extract was added, and the pH was adjusted to 6.95 using an aqueous potassium carbonate solution. The volume of the solution was adjusted to 1500 mL with water, and the solution was placed in a 2 L fermenter to sterilize the medium. Sterilization conditions were 121 ° C for 7 minutes.
(2)培養条件 (2) Culture conditions
[0029] フアーメンター中に窒素ガスを通気し、培地温度を 33°Cで安定させて、凍結濃縮ス ターター(P. freudenreichii ET— 3)を 0. 75mL添カ卩し、培養を開始した。発酵中 の温度は 33°C、 pHは 6. 5に調整し、窒素ガスを通気した。 pHの調整は 40% (wtZ wt)の炭酸カリウム水溶液を使用した。培養方法としては、以下の 5種類を実施した。 [0029] Nitrogen gas was passed through the fermenter, and the temperature of the medium was stabilized at 33 ° C. Then, 0.75 mL of a freeze concentration starter (P. freudenreichii ET-3) was added, and culture was started. During fermentation, the temperature was adjusted to 33 ° C, the pH was adjusted to 6.5, and nitrogen gas was aerated. The pH was adjusted using a 40% (wtZ wt) aqueous potassium carbonate solution. The following five types of culture methods were implemented.
1)培養開始から終了まで窒素ガス通気を継続、 1) Continue nitrogen gas aeration from the start to the end of the culture,
2)培養開始から 72時間後、 96時間後に培養液の 2%重量の乳糖を添加する以外 は 1)と同様、 3)培養開始から 24時間後に窒素ガス通気をエアレーシヨン(2LZ分)に切替え、2) As in 1), except that lactose 2% by weight of the culture solution was added 72 hours and 96 hours after the start of culture. 3) Twenty-four hours after the start of the culture, switch the nitrogen gas aeration to air rate (for 2 LZ),
4)培養開始力も 48時間後にエアレーシヨン(2LZ分)に切替え、 4) After 48 hours, the cultivation starting power was switched to air rate (2LZ).
5)培養開始から 72時間後にエアレーシヨン(2LZ分)に切替え、 5) After 72 hours from the start of the culture, switch to the air rate (for 2LZ),
これらはすべて培養開始 168時間後に培養を終了した。 All of these were terminated after 168 hours from the start of the culture.
(3)結果 (3) Results
[0030] DHNA濃度、乳糖濃度、プロピオン酸菌数、プロピオン酸濃度、酢酸濃度の経時 変化をそれぞれ図 1、図 2、図 3、図 4、図 5に示す。この結果から明らかなように、 4)、 5)により得られた培養物は、 DHNAの濃度が約 45 /z gZmLとなった(図 1)。また、 4)、 5)において、 96時間後に乳糖がほぼ枯渴し(図 2)、培養開始力も増加していた プロピオン酸濃度も緩やかに減少することが確認された(図 4)。プロピオン酸菌数は 、 3)を除き、培養終了時にはすベて 1. O X 1010cfu/mL (10. 0 log cfu/mL) を越え、 4)、 5)は、ほぼ 1. 0 X 10 cfu/mL (l l. 0 log cfu/mL)に達していた (図 3)。 [0030] Time-dependent changes in DHNA concentration, lactose concentration, the number of propionic acid bacteria, propionic acid concentration, and acetic acid concentration are shown in Fig. 1, Fig. 2, Fig. 3, Fig. 4, and Fig. 5, respectively. As is clear from these results, the culture obtained in 4) and 5) had a DHNA concentration of about 45 / z gZmL (FIG. 1). In 4) and 5), it was confirmed that lactose almost died after 96 hours (Fig. 2), and the propionic acid concentration, which had also increased the cultivation starting power, gradually decreased (Fig. 4). Except for 3), the number of propionic acid bacteria exceeded 1.OX 10 10 cfu / mL (10.0 log cfu / mL) at the end of culture, and 4) and 5) were almost 1.0 X 10 cfu / mL (11. 0 log cfu / mL) was reached (Fig. 3).
[0031] 以上より、培養開始力 少なくとも 48時間経過した後に窒素通気力 エアレーショ ンに切替えることで、 DHNAが高濃度に含まれる培養物が得られることが確認された (図 6)。また、切替え時の乳糖濃度は、 4)が 3. 3質量%、 5)が 2. 9質量%であった( 図 2)。 [0031] From the above, it was confirmed that a culture containing a high concentration of DHNA could be obtained by switching to nitrogen aeration aeration after at least 48 hours of the culture start force (Fig. 6). The lactose concentration at the time of switching was 3.3% by mass in 4) and 2.9% by mass in 5) (Fig. 2).
[試験例 2]エアレーシヨン量の検討 [Test Example 2] Examination of air rate
[0032] エアレーシヨン量を変更する以外は、試験例 1の 5)と同様の条件で、培養を行った 。発酵開始から 72時間後に 0. 5LZ分、 1. 0LZ分、 2. 0LZ分、 4. 0LZ分にエア レーシヨンの流量を変更し培養を行った。その結果、流量を 2. 0Z分以上とすること で、培養開始から 144時間後に DHNA濃度が約 40 gZmLとなることがわ力つた。 [0032] Culture was performed under the same conditions as in 5) of Test Example 1 except that the amount of aeration was changed. After 72 hours from the start of fermentation, the culture was carried out with the air flow rate changed to 0.5 LZ, 1.0 LZ, 2.0 LZ, and 4.0 LZ. As a result, it was clarified that the DHNA concentration became about 40 gZmL 144 hours after the start of culture by setting the flow rate to 2.0Z minutes or more.
[実施例 1] [Example 1]
[0033] 脱脂粉乳(明治乳業 (株)製) 180gを水 lOOOgに溶解し、温度を 47°Cに調整した。 180 g of skim milk powder (manufactured by Meiji Dairies Co., Ltd.) was dissolved in 100 g of water, and the temperature was adjusted to 47 ° C.
これにプロテアーゼを 3. 75g添カ卩して 47°Cで 3時間タンパク質の分解を行った。タン パク質分解中の ρΗは 6. 6-6. 8に炭酸カリウム水溶液を用いて調整した。タンパク 質分解後に 80°Cまで加温し 10分保持することでプロテアーゼを失活させ、ビール酵 母エキス 7. 5g、乳糖 15gを添加し、炭酸カリウム水溶液を用いて pHを 6. 95に調整 した。水で溶液の容量を 1500mLに調整し、 2L容量のフアーメンターに入れ、培地 滅菌を行った (乳糖濃度質量約 6. 1%)。滅菌条件は 121°C、 7分とした。滅菌後、フ アーメンター中に窒素ガスを通気し、培地温度を 33°Cで安定させて、凍結濃縮スタ 一ター(P. freudenreichii ET—3)を 0. 75mL添カロし、培養を開始した。培養中の 温度は 33°C、 pHは 6. 5に調整し、窒素ガスを通気した。 pHの調整には 40% (wtZ wt)の炭酸カリウム水溶液を使用した。培養開始 72時間後に窒素ガスの通気力ゝらェ アレーシヨンに切替え、培養開始 168時間後に培養を終了した。エアレーシヨン時の 空気流量は、 2LZ分、撹拌速度は、 150rpmとした。この結果、 DHNAの濃度が 52 gZmLとなる培養物が得られた。 72時間後の乳糖濃度は約 1. 9質量%、プロピ オン酸菌数は 3. 5 X 10lc>cfu/mLであった。 The protein was decomposed at 47 ° C for 3 hours after adding 3.75g of protease to the mixture. During protein degradation, ρ 分解 was adjusted using an aqueous potassium carbonate solution at 6.6-6.8. After proteolysis, the protease was inactivated by heating to 80 ° C and holding for 10 minutes, 7.5 g of beer yeast extract and 15 g of lactose were added, and the pH was adjusted to 6.95 using an aqueous potassium carbonate solution. did. The volume of the solution was adjusted to 1500 mL with water, and the solution was placed in a 2 L fermenter, and the medium was sterilized (lactose concentration mass: about 6.1%). Sterilization conditions were 121 ° C for 7 minutes. After sterilization, nitrogen gas was passed through the fermenter, the medium temperature was stabilized at 33 ° C, and 0.75 mL of freeze-concentration starter (P. freudenreichii ET-3) was added to the culture, and the culture was started. . During the culture, the temperature was adjusted to 33 ° C, the pH was adjusted to 6.5, and nitrogen gas was passed. To adjust the pH, a 40% (wtZ wt) aqueous solution of potassium carbonate was used. The culture was switched to nitrogen gas ventilation 72 hours after the start of the culture, and the culture was terminated 168 hours after the start of the culture. The air flow rate during the air rate was 2 LZ, and the stirring speed was 150 rpm. As a result, a culture having a DHNA concentration of 52 gZmL was obtained. After 72 hours, the lactose concentration was about 1.9% by mass, and the number of propionic acid bacteria was 3.5 × 10 lc> cfu / mL.
[実施例 2] [Example 2]
[0034] 脱脂粉乳(明治乳業 (株)製) 120kgを水 750kgに溶解し、温度を 47°Cに調整した 。これにプロテアーゼを 2. 5kg添加し、 pHを 7. 6に調整し 47°Cで 3時間タンパク質 の分解を行った。分解終了後に 80°Cまで加温し 10分保持することでプロテアーゼを 失活させ、ビール酵母エキス 5kg、乳糖 10kgを添加し、 140°C、 4秒で培地滅菌した 。滅菌開始前の培地 pHは 6. 9であった。滅菌後、水で培地量を 1000Lに合わせ( 乳糖濃度約 6. 1質量%)、フアーメンター中に窒素ガスを 20LZ分で通気し、培地温 度を 33°Cで安定させて、スターター(P. freudenreichii ET— 3)を 3. 0L添加した。 発酵中の温度は 33°C、 pHは 6. 5に調整し、窒素ガスを通気した。 pHの調整は 23 % (wt/wt)の炭酸カリウム水溶液を使用した。培養開始 72時間後に窒素ガスの通 気力もエアレーシヨンに切替えて、培養開始 168時間後に培養を終了した。エアレー シヨン時の空気流量は 200LZ分、撹拌速度は 52rpmとした。この結果、 DHNAの 濃度が 42 gZmLとなる培養物が得られた。なお、培養開始 72時間後の乳糖濃度 は約 1. 5質量%、プロピオン酸菌数は 3. O X 101Gcfu/mLであった。 [0034] 120 kg of skim milk powder (manufactured by Meiji Dairies Co., Ltd.) was dissolved in 750 kg of water, and the temperature was adjusted to 47 ° C. To this, 2.5 kg of protease was added, the pH was adjusted to 7.6, and protein degradation was performed at 47 ° C for 3 hours. After the decomposition was completed, the protease was inactivated by heating to 80 ° C and holding for 10 minutes, 5 kg of brewer's yeast extract and 10 kg of lactose were added, and the medium was sterilized at 140 ° C for 4 seconds. The medium pH before the start of sterilization was 6.9. After sterilization, adjust the volume of the medium to 1000 L with water (lactose concentration approx. 6.1% by mass), inject nitrogen gas into the fermenter for 20 LZ, stabilize the medium temperature at 33 ° C, and start 3.0 L of freudenreichii ET-3) was added. During fermentation, the temperature was adjusted to 33 ° C, the pH was adjusted to 6.5, and nitrogen gas was passed. The pH was adjusted using a 23% (wt / wt) aqueous potassium carbonate solution. At 72 hours after the start of the culture, the gas permeability of the nitrogen gas was also switched to the air rate, and the culture was terminated at 168 hours after the start of the culture. The air flow rate during the air rate was 200 LZ, and the stirring speed was 52 rpm. As a result, a culture having a DHNA concentration of 42 gZmL was obtained. The lactose concentration 72 hours after the start of the culture was about 1.5% by mass, and the number of propionic acid bacteria was 3. OX10 1G cfu / mL.
[実施例 3] [Example 3]
[0035] 前記実施例 2で得られた DHNA含有培養物に、ァスコルビン酸ナトリウムを 1. 0% 、乳糖を 2. 0%添カ卩して、 pHを 8. 0に調整してから、 10°Cで 2週間保存した結果、 D HNA濃度が 55 μ gZmLとなった。 また、乳糖をブドウ糖に替え、同様にして保存したところ、培養終了時より DHNA濃 度が増カロした。 [0035] The DHNA-containing culture obtained in Example 2 was supplemented with sodium ascorbate (1.0%) and lactose (2.0%), and the pH was adjusted to 8.0. As a result of storage at ° C for 2 weeks, the DHNA concentration was 55 µgZmL. When lactose was replaced with glucose and stored in the same manner, the DHNA concentration increased from the end of the culture.
[比較例] [Comparative example]
[0036] 培養中、エアレーシヨンに切り替えず、窒素ガス通気を継続する以外は、実施例 1と すべて同様の条件で行った。この結果、 DHNAの濃度が 32 gZmLとなる培養物 が得られた。 [0036] During the cultivation, all the operations were performed under the same conditions as in Example 1 except that the nitrogen gas flow was continued without switching to the air rate. As a result, a culture having a DHNA concentration of 32 gZmL was obtained.
[実施例 4] [Example 4]
[0037] 前記実施例 1で得られた DHNA含有培養物を 120gのプレーンヨーグルト(明治乳 業 (株)製)に加え、調製したヨーグルトの官能評価を表 1及び表 2に示す。本発明法 により得られた DHNA含有培養物を加えたヨーグルトは、 DHNA濃度が高ぐ従来 法 (プレーンヨーグルトに比較例で得られた DHNA含有培養物を添加したもの)と比 較し、酸味がなぐ苦みも感じられないことが確認された。 [0037] The DHNA-containing culture obtained in Example 1 was added to 120 g of plain yogurt (manufactured by Meiji Dairies Co., Ltd.), and the sensory evaluation of the prepared yogurt is shown in Tables 1 and 2. The yogurt to which the DHNA-containing culture obtained by the method of the present invention was added had a sour taste as compared with the conventional method in which the DHNA concentration was high (the DHNA-containing culture obtained in Comparative Example was added to plain yogurt). It was confirmed that no bitterness was felt.
[0038] [表 1] 項目 風味 酸味 苦味 総合評価 [0038] [Table 1] Item Flavor Sourness Bitterness Overall evaluation
実施例 1で調製した 〇 〇 - © © 調製 prepared in Example 1-©
培養物 Culture
比較例で調製した 〇 〇 X 厶 〇 〇 X mm prepared in Comparative Example
培養物 Culture
X:不良 厶:やや不良 〇:普通 ◎優良 X: Bad Mu: Somewhat bad 〇: Normal ◎ Excellent
プレーンヨーグルトに 1 g添加 Add 1 g to plain yogurt
プレーンヨーグルト: 120g Plain yogurt: 120g
[0039] [表 2] 項目 風味 酸味 苦味 総合評価 [Table 2] Item Flavor Sourness Bitterness Overall evaluation
実施例 1で調製した Δ 〇 - 〇 Δ 〇-調製 prepared in Example 1
培養物 Culture
比較例で調製した Δ Δ X X Δ Δ X X prepared in Comparative Example
培養物 Culture
X:不良 △:やや不良 〇:普通 ◎優良 一:感じない X: Poor △: Slightly poor 〇: Normal ◎ Excellent I: Not felt
プレーンヨーグルトに 2g添加 Add 2g to plain yogurt
プレーンヨーグルト: 120g Plain yogurt: 120g
[0040] [実施例 5] [Example 5]
[0041] 脱脂粉乳(明治乳業 (株)製) 120kgを水 750kgに溶解し、温度を 47°Cに調整した 。これにプロテアーゼを 2. 5kg添加し、 pHを 7. 6に調整し 47°Cで 6時間タンパク質 の分解を行った。分解終了後に 80°Cまで加温し 10分保持することでプロテアーゼを 失活させ、ビール酵母エキス 5kg、乳糖 10kgを添加し、 140°C、 4秒で培地滅菌した 。滅菌開始前の培地 pHは 6. 9であった。滅菌後、水で培地量を 1000Lに合わせ( 乳糖濃度約 6. 1質量%)、フアーメンター中に窒素ガスを 20LZ分で通気し、培地温 度を 33°Cで安定させて、スターター(P. freudenreichii ET— 3)を 3. 0L添加した。 培養中の温度は 33°C、 pHは 6. 5に調整し、窒素ガスを通気した。 pHの調整は 23 % (wt/wt)の炭酸カリウム水溶液を使用した。培養開始 72時間後に窒素ガスの通 気力もエアレーシヨンに切替えて、培養開始 168時間後に培養を終了した。エアレー シヨン時の空気流量は 200LZ分、撹拌速度は 52rpmとした。この結果、 DHNAの 濃度が 48 gZmLとなる培養物が得られた。なお、培養開始 72時間後の乳糖濃度 は約 3. 0質量%、プロピオン酸菌数は 2. 9 X 101Gcfu/mLであった。 [0041] 120 kg of skim milk powder (manufactured by Meiji Dairies Co., Ltd.) was dissolved in 750 kg of water, and the temperature was adjusted to 47 ° C. . To this, 2.5 kg of protease was added, the pH was adjusted to 7.6, and protein degradation was performed at 47 ° C for 6 hours. After the decomposition was completed, the protease was inactivated by heating to 80 ° C and holding for 10 minutes, 5 kg of brewer's yeast extract and 10 kg of lactose were added, and the medium was sterilized at 140 ° C for 4 seconds. The medium pH before the start of sterilization was 6.9. After sterilization, adjust the volume of the medium to 1000 L with water (lactose concentration approx. 6.1% by mass), inject nitrogen gas into the fermenter for 20 LZ, stabilize the medium temperature at 33 ° C, and start 3.0 L of freudenreichii ET-3) was added. During the culture, the temperature was adjusted to 33 ° C, the pH was adjusted to 6.5, and nitrogen gas was passed. The pH was adjusted using a 23% (wt / wt) aqueous potassium carbonate solution. At 72 hours after the start of the culture, the gas permeability of the nitrogen gas was also switched to the air rate, and the culture was terminated at 168 hours after the start of the culture. The air flow rate during the air rate was 200 LZ, and the stirring speed was 52 rpm. As a result, a culture having a DHNA concentration of 48 gZmL was obtained. The lactose concentration 72 hours after the start of the culture was about 3.0% by mass, and the number of propionic acid bacteria was 2.9 × 10 1 G cfu / mL.
[実施例 6] [Example 6]
前記実施例 5で得られた DHNA含有培養物に、ァスコルビン酸ナトリウムを 1. 0% 、乳糖を 1. 0%添カ卩して、 pHを 8. 0に調整してから、 10°Cで 2週間保存した結果、 D HNA濃度が 60 μ gZmLとなった。 The DHNA-containing culture obtained in Example 5 was added with 1.0% sodium ascorbate and 1.0% lactose to adjust the pH to 8.0, and then adjusted to 10 ° C. As a result of storage for 2 weeks, the DHNA concentration was 60 μg ZmL.
Claims
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004278620A AU2004278620B2 (en) | 2003-10-01 | 2004-09-30 | Process for producing 1,4-dihydroxy-2-naphthoic acid |
| JP2005514449A JP4613132B2 (en) | 2003-10-01 | 2004-09-30 | Process for producing 1,4-dihydroxy-2-naphthoic acid |
| EP12001430.3A EP2463376B1 (en) | 2003-10-01 | 2004-09-30 | Food and beverages for treating metabolic osteopathy |
| CA2540507A CA2540507C (en) | 2003-10-01 | 2004-09-30 | Process for producing 1,4-dihydoxy-2-naphthoic acid |
| US10/574,283 US7507563B2 (en) | 2003-10-01 | 2004-09-30 | Process for producing 1, 4-dihydroxy-2-naphthoic acid |
| EP12001429.5A EP2463375B1 (en) | 2003-10-01 | 2004-09-30 | Food and beverages for treating abdominal discomfort |
| NZ546286A NZ546286A (en) | 2003-10-01 | 2004-09-30 | Process for producing 1,4-dihydroxy-2-naphthoic acid |
| EP04788422.6A EP1669458B1 (en) | 2003-10-01 | 2004-09-30 | Process for producing 1,4-dihydroxy-2-naphthoic acid |
| KR1020067006133A KR101116244B1 (en) | 2003-10-01 | 2006-03-29 | Preparation of 1,4-dihydroxy-2-naphthoic acid |
| US12/187,065 US8758842B2 (en) | 2003-10-01 | 2008-08-06 | Process for producing 1,4-dihydroxy-2-naphthoic acid |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003343211 | 2003-10-01 | ||
| JP2003-343211 | 2003-10-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005033323A1 true WO2005033323A1 (en) | 2005-04-14 |
Family
ID=34419286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2004/014394 Ceased WO2005033323A1 (en) | 2003-10-01 | 2004-09-30 | Process for producing 1,4-dihydoxy-2-naphthoic acid |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7507563B2 (en) |
| EP (3) | EP2463376B1 (en) |
| JP (1) | JP4613132B2 (en) |
| KR (1) | KR101116244B1 (en) |
| CN (1) | CN100422337C (en) |
| AU (1) | AU2004278620B2 (en) |
| CA (1) | CA2540507C (en) |
| NZ (1) | NZ546286A (en) |
| WO (1) | WO2005033323A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014196355A (en) * | 2008-02-29 | 2014-10-16 | 株式会社明治 | Antiallergic agent |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100247500A1 (en) * | 2007-11-27 | 2010-09-30 | Kakuhei Isawa | Agent and method for improving survivability of lactic acid bacterium, and food composition |
| US11179427B2 (en) | 2013-01-21 | 2021-11-23 | Eth Zurich | Baby food composition comprising viable propionic acid-producing bacteria |
| EP3294308A4 (en) | 2015-05-14 | 2019-03-06 | University of Puerto Rico | METHOD FOR RESTORING THE MICROBIOTE OF INFANTS |
| WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
| CN111227038B (en) * | 2018-11-29 | 2023-02-24 | 内蒙古伊利实业集团股份有限公司 | Double-fermentation double-protein milk beverage and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2102332A1 (en) * | 1996-01-03 | 1997-07-16 | Invest Y Desarrollo Agroindust | Process for the production of vitamin B12 from polluting wastes in the citrus growing industries. |
| JP2002540760A (en) * | 1998-12-18 | 2002-12-03 | デーエスエム・ナムローゼ・フェンノートシャップ | Improved production method of vitamin B12 |
| WO2003016544A1 (en) * | 2001-08-10 | 2003-02-27 | Meiji Dairies Corporation | Process for producing 1,4-dihydroxy-2-naphthoic acid |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3315826B2 (en) * | 1994-04-26 | 2002-08-19 | 明治乳業株式会社 | Bifidobacterium growth promotion composition |
| JP3017456B2 (en) | 1997-05-08 | 2000-03-06 | 明治乳業株式会社 | High-concentration culture method and culture product of propionic acid bacteria and processed product thereof |
| KR101003344B1 (en) * | 2003-03-26 | 2010-12-23 | 메이지 데어리스 코포레이션 | Method of stabilizing 1,4-dihydroxy-2-naphthoic acid |
-
2004
- 2004-09-30 EP EP12001430.3A patent/EP2463376B1/en not_active Expired - Lifetime
- 2004-09-30 WO PCT/JP2004/014394 patent/WO2005033323A1/en not_active Ceased
- 2004-09-30 AU AU2004278620A patent/AU2004278620B2/en not_active Ceased
- 2004-09-30 US US10/574,283 patent/US7507563B2/en not_active Expired - Lifetime
- 2004-09-30 EP EP12001429.5A patent/EP2463375B1/en not_active Expired - Lifetime
- 2004-09-30 CN CNB2004800284544A patent/CN100422337C/en not_active Expired - Fee Related
- 2004-09-30 EP EP04788422.6A patent/EP1669458B1/en not_active Expired - Lifetime
- 2004-09-30 CA CA2540507A patent/CA2540507C/en not_active Expired - Lifetime
- 2004-09-30 NZ NZ546286A patent/NZ546286A/en not_active IP Right Cessation
- 2004-09-30 JP JP2005514449A patent/JP4613132B2/en not_active Expired - Fee Related
-
2006
- 2006-03-29 KR KR1020067006133A patent/KR101116244B1/en not_active Expired - Fee Related
-
2008
- 2008-08-06 US US12/187,065 patent/US8758842B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2102332A1 (en) * | 1996-01-03 | 1997-07-16 | Invest Y Desarrollo Agroindust | Process for the production of vitamin B12 from polluting wastes in the citrus growing industries. |
| JP2002540760A (en) * | 1998-12-18 | 2002-12-03 | デーエスエム・ナムローゼ・フェンノートシャップ | Improved production method of vitamin B12 |
| WO2003016544A1 (en) * | 2001-08-10 | 2003-02-27 | Meiji Dairies Corporation | Process for producing 1,4-dihydroxy-2-naphthoic acid |
Non-Patent Citations (7)
| Title |
|---|
| HOJO K. ET AL.: "Bifidogenic growth stimulator produced by propionic acid bacteria", MILK SCIENCE, vol. 49, no. 3, 2000, pages 161 - 167, XP008051230 * |
| ISAWA K. ET AL.: "Isolation and identification of a new bifidogenic growth stimulator produced by propionibacterium freudenreichii ET-3", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 66, no. 3, 2002, pages 679 - 681, XP008041283 * |
| ISHIDA J. ET AL.: "Propion-sankin no kenki oyobi koki baiyo ni yoru bifidobacteria tokuiteki zoshoku sokushin busshitsu no seisan", 2002 NENDO (HEISEI 14 NENDO) JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY TAIKAI KOEN YOSHISHU, 2002, pages 8, XP008107772 * |
| MIYANO K. ET AL.: "Propion-sankin no roka baiyo oyobi shuki seigyo baiyo ni yoru vitamin B12 no seisan", THE SOCIETY OF CHEMICAL ENGINEERS, JAPAN SHUKI TAIKAI KENKYU HAPPYO KOEN YOSHISHU, vol. 30, no. 1, 1997, pages 316, XP008107770 * |
| OKADA Y. ET AL.: "Propion-sankin ni yoru nyusei hakkobutsu seibun no DHNA no DSS choen ni taisuru koensho sayo no kento", DIGESTIVE ORGAN AND IMMUNOLOGY, no. 40, 10 June 2003 (2003-06-10), pages 58 - 60 * |
| See also references of EP1669458A4 * |
| YE K. ET AL.: "Efficient production of vitamin B12 from propionic acid bacteria under periodic variation of dissolved oxygen concentration", J. FERMENT. BIOENG., vol. 82, no. 5, 1996, pages 484 - 491, XP002105067 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014196355A (en) * | 2008-02-29 | 2014-10-16 | 株式会社明治 | Antiallergic agent |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2463375B1 (en) | 2019-08-21 |
| US7507563B2 (en) | 2009-03-24 |
| EP2463376B1 (en) | 2019-08-28 |
| EP2463375A3 (en) | 2013-01-30 |
| CN100422337C (en) | 2008-10-01 |
| CN1860236A (en) | 2006-11-08 |
| AU2004278620A1 (en) | 2005-04-14 |
| EP1669458B1 (en) | 2016-03-16 |
| US8758842B2 (en) | 2014-06-24 |
| KR101116244B1 (en) | 2012-03-09 |
| EP1669458A4 (en) | 2011-05-25 |
| US20090232940A1 (en) | 2009-09-17 |
| NZ546286A (en) | 2008-10-31 |
| CA2540507A1 (en) | 2005-04-14 |
| EP2463376A2 (en) | 2012-06-13 |
| KR20060087594A (en) | 2006-08-02 |
| CA2540507C (en) | 2015-09-29 |
| AU2004278620B2 (en) | 2010-07-15 |
| EP2463376A3 (en) | 2013-01-30 |
| EP2463375A2 (en) | 2012-06-13 |
| JPWO2005033323A1 (en) | 2007-11-15 |
| US20070066685A1 (en) | 2007-03-22 |
| EP1669458A1 (en) | 2006-06-14 |
| JP4613132B2 (en) | 2011-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shahani et al. | Role of dietary lactobacilli in gastrointestinal microecology | |
| Fernández-Garía et al. | The addition of oat fiber and natural alternative sweeteners in the manufacture of plain yogurt | |
| US4702923A (en) | Lyophilized kefir yoghurt health food | |
| JP4070721B2 (en) | Process for producing 1,4-dihydroxy-2-naphthoic acid | |
| JP2000210075A (en) | Lactic acid bacterium having high productivity of gamma- aminobutyric acid, fermented food with high content of gamma-aminobutyric acid using the same lactic acid bacterium and its production | |
| US10092605B2 (en) | Food composition, containing Lactococcus strain as active ingredient, for alleviating hangover | |
| US8758842B2 (en) | Process for producing 1,4-dihydroxy-2-naphthoic acid | |
| WO2005099725A1 (en) | Preventive and/or remedy for inflammatory bowel diseases | |
| TWI502070B (en) | Production method of γ-butyric acid | |
| JP2002058425A (en) | Fermented food containing conjugated fatty acids and method for producing the same | |
| CN115851520B (en) | Lactobacillus paracasei and application thereof | |
| JP2005198578A (en) | METHOD FOR PRODUCING gamma-AMINOBUTYRIC ACID AND FERMENTED LIQUID YIELDED THEREBY | |
| RU2108724C1 (en) | Composition of cultured milk product for children alimentation and method for it production | |
| RU2185436C2 (en) | Bacterium consortium for fermented-milk foodstuffs preparing | |
| JP7513336B1 (en) | Method for producing powder containing gamma-aminobutyric acid (GABA) and products using the same | |
| JP3261571B2 (en) | Method for improving survival of bifidobacteria | |
| JP2007104977A (en) | Method for producing substance containing gamma aminobutyric acid | |
| JPWO2006093013A1 (en) | Serum cholesterol lowering material, method for producing the same, food composition and pharmaceutical composition having serum cholesterol lowering action | |
| KR100225533B1 (en) | Bifidobacterium growth promotr | |
| JP4653785B2 (en) | Process for producing 1,4-dihydroxy-2-naphthoic acid | |
| JP2024097852A (en) | Method for producing an inclusion complex in which equol is included in cyclodextrin | |
| JPH06253734A (en) | Method for improving survivability of bifidus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200480028454.4 Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2005514449 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004788422 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2540507 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020067006133 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004278620 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007066685 Country of ref document: US Ref document number: 546286 Country of ref document: NZ Ref document number: 10574283 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004278620 Country of ref document: AU |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004788422 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020067006133 Country of ref document: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: 10574283 Country of ref document: US |